Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Non-Current Debt: 2009-2020

Historic Non-Current Debt for Amicus Therapeutics (FOLD) over the last 6 years, with Jun 2020 value amounting to $147.8 million.

  • Amicus Therapeutics' Non-Current Debt rose 0.57% to $147.8 million in Q2 2020 from the same period last year, while for Jun 2020 it was $147.8 million, marking a year-over-year increase of 0.57%. This contributed to the annual value of $147.4 million for FY2019, which is 0.44% up from last year.
  • Latest data reveals that Amicus Therapeutics reported Non-Current Debt of $147.8 million as of Q2 2020, which was up 0.18% from $147.6 million recorded in Q1 2020.
  • Amicus Therapeutics' 5-year Non-Current Debt high stood at $147.8 million for Q2 2020, and its period low was $38.5 million during Q1 2016.
  • Over the past 3 years, Amicus Therapeutics' median Non-Current Debt value was $147.1 million (recorded in 2019), while the average stood at $147.1 million.
  • Data for Amicus Therapeutics' Non-Current Debt shows a peak YoY soared of 318.21% (in 2016) over the last 5 years.
  • Amicus Therapeutics' Non-Current Debt (Quarterly) stood at $44.0 million in 2016, then reached $146.7 million in 2018, then climbed by 0.44% to $147.4 million in 2019, then rose by 0.57% to $147.8 million in 2020.
  • Its Non-Current Debt stands at $147.8 million for Q2 2020, versus $147.6 million for Q1 2020 and $147.4 million for Q4 2019.